Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Amylin Analog Pramlintide Induces Migraine-like Attacks in Patients

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Genetic Susceptibility Loci in Genomewide Association Study of Cluster Headache

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. MRI in Neuromuscular Diseases: An Emerging Diagnostic Tool and Biomarker for Prognosis and Efficacy

    Research output: Contribution to journalReviewpeer-review

  3. Optic Disc Classification by Deep Learning versus Expert Neuro-Ophthalmologists

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. A New Glycogen Storage Disease Caused by a Dominant PYGM Mutation

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. The chronobiology of migraine: a systematic review

    Research output: Contribution to journalReviewpeer-review

  2. PEARL study protocol: a real-world study of fremanezumab effectiveness in patients with chronic or episodic migraine

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Symptomatic migraine: A systematic review to establish a clinically important diagnostic entity

    Research output: Contribution to journalReviewpeer-review

  4. Timing and durability of response to erenumab in patients with chronic migraine

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

OBJECTIVE: Migraine is a prevalent and disabling neurological disease. Its genesis is poorly understood, and there remains unmet clinical need. We aimed to identify mechanisms and thus novel therapeutic targets for migraine using human models of migraine and translational models in animals, with emphasis on amylin, a close relative of calcitonin gene-related peptide (CGRP).

METHODS: Thirty-six migraine without aura patients were enrolled in a randomized, double-blind, 2-way, crossover, positive-controlled clinical trial study to receive infusion of an amylin analogue pramlintide or human αCGRP on 2 different experimental days. Furthermore, translational studies in cells and mouse models, and rat, mouse and human tissue samples were conducted.

RESULTS: Thirty patients (88%) developed headache after pramlintide infusion, compared to 33 (97%) after CGRP (p = 0.375). Fourteen patients (41%) developed migraine-like attacks after pramlintide infusion, compared to 19 patients (56%) after CGRP (p = 0.180). The pramlintide-induced migraine-like attacks had similar clinical characteristics to those induced by CGRP. There were differences between treatments in vascular parameters. Human receptor pharmacology studies showed that an amylin receptor likely mediates these pramlintide-provoked effects, rather than the canonical CGRP receptor. Supporting this, preclinical experiments investigating symptoms associated with migraine showed that amylin treatment, like CGRP, caused cutaneous hypersensitivity and light aversion in mice.

INTERPRETATION: Our findings propose amylin receptor agonism as a novel contributor to migraine pathogenesis. Greater therapeutic gains could therefore be made for migraine patients through dual amylin and CGRP receptor antagonism, rather than selectively targeting the canonical CGRP receptor. ANN NEUROL 2021.

Original languageEnglish
JournalAnnals of Neurology
Volume89
Issue number6
Pages (from-to)1157-1171
Number of pages15
ISSN0364-5134
DOIs
Publication statusPublished - Jun 2021

ID: 65608616